Dave, I suspect that some structural info will be in this report:
Drug Metab Dispos 1997 Oct;25(10):1144-1149
Oxidative metabolism of a rexinoid and rapid phase II
metabolite identification by mass spectrometry.
Shirley MA, Wheelan P, Howell SR, Murphy RC
Department of Drug Safety and Disposition, Ligand Pharmaceuticals, Inc., San Diego, CA 92121,
USA.
LGD1069 (Targretin), a retinoid "X" receptor-selective ligand, or rexinoid, is in clinical trials for
treating cancer. Biologically-active oxidized LGD1069 metabolites have been observed in patient
plasma samples, making corresponding structural characterizations necessary. Formation of multiple
metabolite isomers in vivo has created technical challenges in metabolite structural analysis; however,
mass spectrometry (MS) was able to pinpoint two sites of Phase I metabolism. A carbon-13
trideuterated analog was used as an isotopic marker to probe Phase II metabolism of LGD1069.
Rats were orally gavaged with an equimolar mixture of LGD1069 and [13C2H3]LGD1069, then
anesthetized prior to bile-duct cannulation. Bile was collected for 7 hr, extracted, and concentrated.
Recovered metabolites were analyzed by narrow-bore, gradient liquid chromatography (LC) with
negative ion, electrospray ionization MS detection. When resultant total ion chromatograms were
interrogated for mass spectra exhibiting isotope clusters separated by 4 daltons, 13 such clusters
corresponding to Phase II LGD1069 metabolites of nine different molecular weights were detected.
Acyl-glucuronide and taurine conjugates of both parent compound and hydroxy-LGD1069 were
observed. The sulfate and taurine conjugates of oxo-LGD1069 were also identified, as were
6,7-dihydroxy-LGD1069 taurine, LGD1069 ether glucuronide, and a secondary conjugate (taurine)
of the latter. Identities of selected conjugates were confirmed by MS/MS. The results of this study
demonstrate that when combined with traditional GC/MS and MS/MS data, the isotope cluster
technique can provide powerful selectivity in identifying numerous Phase II drug metabolites during a
single LC/MS analysis.
PMID: 9321517, UI: 97464548 |
